GH Research PLC(GHRS)Earnings, Financials & Key Ratios
GHRS•NASDAQ
$26.89
Price updated Jul 7, 2026
AboutGH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.Show more
- Revenue$0
- EBITDA-$60M-20.7%
- Net Income-$48M-23.9%
- EPS (Diluted)-0.79-5.3%
- ROE-21.04%-7.5%
GHRS Price & Volume
GH Research PLC (GHRS) stock price & volume — 10-year historical chart
Loading chart...
GHRS Growth Metrics
GH Research PLC (GHRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-33.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-16.46%
Return on Capital
10 Years-26.24%
5 Years-18.3%
3 Years-23.07%
Last Year-26.43%
GHRS Recent Earnings
GH Research PLC (GHRS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.31-14.8%
$0.27
Rev
—
—
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.23+20.7%
$0.29
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.23+0.0%
$0.23
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.15+31.8%
$0.22
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.31vs $0.27-14.8% | — |
| Q2 2026 | Mar 5, 2026 | $0.23vs $0.29+20.7% | — |
| Q4 2025 | Nov 6, 2025 | $0.23vs $0.23+0.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.15vs $0.22+31.8% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for GH Research PLC (GHRS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $26.89 | $1.84B | -34.04 | — | — | -21.04% | — | |
| $12.99 | $1.25B | -4.22 | — | — | -151.02% | — | |
| $5.19 | $1.91B | -1.78 | 1227.6% | -19019.44% | -366.21% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $6.09 | $303.86M | -13.66 | — | — | -81% | — | |
| $4.16 | $71.91M | -3.10 | — | -1070.26% | — | — |
Compare GHRS vs Peers
GH Research PLC (GHRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GHRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GHRS Frequently Asked Questions
GH Research PLC (GHRS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is GHRS profitable?
GH Research PLC (GHRS) reported a net loss of $56.4M for fiscal year 2025.
Dividend & Returns
What is GHRS's return on equity?
GH Research PLC (GHRS) has a return on equity (ROE) of -21.0%. Negative ROE indicates the company is unprofitable.
What is GH Research PLC's free cash flow?
GH Research PLC (GHRS) had negative free cash flow of $46.5M in fiscal year 2025, likely due to heavy capital investments.